Precision Medicine in Chinese Patients With Young Onset Diabetes
Launched by CHINESE UNIVERSITY OF HONG KONG · Aug 6, 2019
Trial Information
Current as of September 08, 2025
Unknown status
Keywords
ClinConnect Summary
Patients with young onset diabetes (YOD) are one of the most challenging groups of patients due to their long disease duration, complex causes, delayed interventions, psychosocial stress, poor adherence and frequent default. The investigator's previous studies indicate that provision of biogenetic information improved satisfaction, reduced ambiguity and improved self-efficacy in patients with T2D. Provision of personalized information using the web-based Joint Asia Diabetes Evaluation (JADE) Technology with risk stratification and decision support empowers better self care and medical inter...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Part 1: Prospective cohort of Chinese with type 2 diabetes
- • Between 1995 and December 2004, 10,129 patients were assessed using structured protocol to esetablish the HKDR and of them, we have measured GADA and CP in 1400 patients with YOD. In this study, we shall measure CP and GADA in 4000 subjects from the HKDR with available GWAS data irrespective of their age of diagnosis. These samples were linked to our various databases by a unique identification code which will enable us to track the clinical outcomes including development of complications.
- • Part 2: Family-based cohort of first-degree relatives of diabetic probands
- • We shall utilize the resource of the HKDFS and control subjects to discover novel genetic variants of YOD. Subjects will be selected based on their status with or without diabetes. In 2012-2013, we ascertained the glycemic status of 365 siblings in the HKDFS and 452 participants of the community-based LKS cohort (aged 18-55 years) without diabetes at baseline (1998-2002).
- • In this cohort, 167 participants (53.7%) with a family history of YOD, 68 participants (30.1%) with a family history of late onset diabetes and 40 (14.4%) participants without family history of diabetes developed diabetes. Amongst the 313 siblings with family history of YOD, 167 had diabetes at baseline or developed diabetes during follow up and 146 did not develop diabetes after 13 years giving 100-120 sibpairs for linkage analysis. These sequence data will be imputed with 500 YOD patients and 500 control subjects with exome data as well as 6000 patients in the HKDR with GWAS data for analysis for validation purpose.
- • Part 3: RCT (PRISM)
- • Non-type 1 diabetes (T1D)
- • Chinese ethnicity
- • Age between 18-50 years inclusive
- • Age at diabetes diagnosis 40 years
- • Able to understand study requirements and voluntarily agree to participate by providing written informed consent
- Exclusion Criteria:
- Part 1/2:
- • Subjects in the HKDR, HKFDS and LKS cohorts without or insuffiicent amount of biosamples for assays or sequencing.
- Part 3:
- • T1D, defined by presentation with diabetic ketoacidosis or insulin requirement within 6 months of diagnosis.
- • Reduced life expectancy due to terminal illness or otherwise deemed not appropriate per discretion of the investigator
About Chinese University Of Hong Kong
The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sha Tin, , Hong Kong
Patients applied
Trial Officials
Juliana Chan, MD
Principal Investigator
Chinese University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials